Parameter
| Biomarker | biCEBPA | Full name | Biallelic CCAAT/Enhancer Binding Protein Alpha gene mutation | Molecular Type | Nucleic acid (DNA) |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis | ||
| Disease | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Whole blood/bone marrow (genomic sequencing) | ||
| Pathobiological Mechanisms | The key transcription factor for hematopoietic myeloid cell differentiation, double allele mutations affect cell differentiation regulation. | ||||
| Clinical Availability Status | Clinical validation/guideline recommendation: WHO defines independent subtypes, and the ELN guidelines incorporate prognostic stratification. | ||||
| Notes and Dynamics | Single mutations are associated with a favorable prognosis, whereas the presence of a TET2 mutation is associated with a poorer prognosis; the related immunophenotype holds promise for disease screening. | ||||